Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycerol-Phenylbutyrate in Allan-Herndon-Dudley Syndrome
NCT05019417Phase 3Unknown
- Sponsor
- Kaplan Medical Center
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of glycerol phenylbutyrate in Allan-Herndon-Dudley syndrome (AHDS), sponsored by Kaplan Medical Center. Primary endpoints: Serum T3 levels at 4 months, Serum T4 levels at 4 months and 1 more. Status: unknown.
02
Drugs
glycerol phenylbutyrate
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on NCT05019417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019417.